NVO vs. CLBT
NVO (Novo Nordisk A/S) and CLBT (Cellebrite DI Ltd.) are both stocks. NVO operates in Drug Manufacturers - General (Healthcare), while CLBT operates in Software - Infrastructure (Technology). Over the past 3 years, NVO returned -15.59%/yr vs 26.12%/yr for CLBT. At a 0.16 correlation, their price movements are largely independent.
Performance
NVO vs. CLBT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NVO achieves a -10.74% return, which is significantly higher than CLBT's -28.79% return.
NVO
- 1D
- -0.18%
- 1M
- -6.80%
- YTD
- -10.74%
- 6M
- -9.50%
- 1Y
- -43.34%
- 3Y*
- -15.59%
- 5Y*
- 2.92%
- 10Y*
- 7.56%
CLBT
- 1D
- 0.00%
- 1M
- 6.12%
- YTD
- -28.79%
- 6M
- -31.77%
- 1Y
- -20.94%
- 3Y*
- 26.12%
- 5Y*
- —
- 10Y*
- —
NVO vs. CLBT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | -10.74% | -39.22% | -15.93% | 54.84% | 22.66% | 9.40% |
CLBT Cellebrite DI Ltd. | -28.79% | -18.16% | 154.39% | 98.62% | -45.64% | -23.40% |
Correlation
The correlation between NVO and CLBT is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Aug 31, 2021 | 0.16 |
Fundamentals
NVO:
$195.21B
CLBT:
$3.24B
NVO:
DKK 27.42
CLBT:
$0.29
NVO:
10.34
CLBT:
44.77
NVO:
0.44
CLBT:
0.09
NVO:
3.85
CLBT:
6.48
NVO:
6.21
CLBT:
6.34
NVO:
DKK 327.80B
CLBT:
$496.43M
NVO:
DKK 268.30B
CLBT:
$416.33M
NVO:
DKK 181.54B
CLBT:
$84.98M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NVO vs. CLBT — Risk / Return Rank
NVO
CLBT
NVO vs. CLBT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and Cellebrite DI Ltd. (CLBT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NVO | CLBT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.43 | ||
| Sortino ratioReturn per unit of downside risk | -0.73 | ||
| Omega ratioGain probability vs. loss probability | 0.85 | 0.96 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | -0.80 | -0.48 | -0.32 |
| Martin ratioReturn relative to average drawdown | -1.18 | -1.05 | -0.14 |
Loading charts...
Drawdowns
NVO vs. CLBT - Drawdown Comparison
The maximum NVO drawdown since its inception was -74.70%, which is greater than CLBT's maximum drawdown of -67.74%. Use the drawdown chart below to compare losses from any high point for NVO and CLBT.
Loading charts...
Drawdown Indicators
| NVO | CLBT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.70% | -67.74% | -6.96% |
Max Drawdown (1Y)Largest decline over 1 year | -54.34% | -43.61% | -10.73% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -57.58% | -17.12% |
Max Drawdown (5Y)Largest decline over 5 years | -74.70% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -74.70% | — | — |
Current DrawdownCurrent decline from peak | -68.11% | -50.62% | -17.49% |
Average DrawdownAverage peak-to-trough decline | -17.79% | -34.54% | +16.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 37.62% | 20.06% | +17.56% |
Volatility
NVO vs. CLBT - Volatility Comparison
The current volatility for Novo Nordisk A/S (NVO) is 10.68%, while Cellebrite DI Ltd. (CLBT) has a volatility of 20.18%. This indicates that NVO experiences smaller price fluctuations and is considered to be less risky than CLBT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NVO | CLBT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.68% | 20.18% | -9.50% |
Volatility (6M)Calculated over the trailing 6-month period | 38.04% | 40.18% | -2.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 51.88% | 51.73% | +0.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.33% | 50.28% | -11.95% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.56% | 50.28% | -17.72% |
Dividends
NVO vs. CLBT - Dividend Comparison
NVO's dividend yield for the trailing twelve months is around 4.11%, while CLBT has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CLBT Cellebrite DI Ltd. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.11% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
NVO vs. CLBT - Financials Comparison
This section allows you to compare key financial metrics between Novo Nordisk A/S and Cellebrite DI Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVO vs. CLBT - Profitability Comparison
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
CLBT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cellebrite DI Ltd. reported a gross profit of 105.88M and revenue of 128.30M. Therefore, the gross margin over that period was 82.5%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
CLBT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cellebrite DI Ltd. reported an operating income of 9.23M and revenue of 128.30M, resulting in an operating margin of 7.2%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
CLBT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cellebrite DI Ltd. reported a net income of 10.94M and revenue of 128.30M, resulting in a net margin of 8.5%.
Frequently Asked Questions
NVO and CLBT have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLBT has higher volatility (20.18%) compared to NVO (10.68%). In terms of maximum drawdown, NVO dropped -74.70% vs CLBT's -67.74%.
CLBT currently has the higher Sharpe Ratio (-0.41 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NVO and CLBT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer